Titre : Thymocytes

Thymocytes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Probability
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Thymocytes : Questions médicales les plus fréquentes", "headline": "Thymocytes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Thymocytes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-03", "dateModified": "2025-03-30", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Thymocytes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Cellules", "url": "https://questionsmedicales.fr/mesh/D002477", "about": { "@type": "MedicalCondition", "name": "Cellules", "code": { "@type": "MedicalCode", "code": "D002477", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11" } } }, "about": { "@type": "MedicalCondition", "name": "Thymocytes", "alternateName": "Thymocytes", "code": { "@type": "MedicalCode", "code": "D060168", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Lie Wang", "url": "https://questionsmedicales.fr/author/Lie%20Wang", "affiliation": { "@type": "Organization", "name": "Institute of Immunology, Zhejiang University School of Medicine, Hangzhou, China." } }, { "@type": "Person", "name": "Ravshan Z Sabirov", "url": "https://questionsmedicales.fr/author/Ravshan%20Z%20Sabirov", "affiliation": { "@type": "Organization", "name": "Institute of Biophysics and Biochemistry, National University of Uzbekistan, Tashkent, Uzbekistan." } }, { "@type": "Person", "name": "Chao Chen", "url": "https://questionsmedicales.fr/author/Chao%20Chen", "affiliation": { "@type": "Organization", "name": "Special Key Laboratory of Gene Detection and Therapy of the Guizhou Province, Zunyi Medical University, Zunyi, China." } }, { "@type": "Person", "name": "Lin Xu", "url": "https://questionsmedicales.fr/author/Lin%20Xu", "affiliation": { "@type": "Organization", "name": "Special Key Laboratory of Gene Detection and Therapy of the Guizhou Province, Zunyi Medical University, Zunyi, China, xulinzhouya@163.com." } }, { "@type": "Person", "name": "Pilar López-Nieva", "url": "https://questionsmedicales.fr/author/Pilar%20L%C3%B3pez-Nieva", "affiliation": { "@type": "Organization", "name": "Genome Dynamics and Function Program, Genome Decoding Department, Severo Ochoa Molecular Biology Center (CBMSO), CSIC-Madrid Autonomous University, 28049 Madrid, Spain." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Cluster-Based Toxicity Estimation of Osteoradionecrosis via Unsupervised Machine Learning: Moving Beyond Single Dose-Parameter Normal Tissue Complication Probability by Using Whole Dose-Volume Histograms for Cohort Risk Stratification.", "datePublished": "2023-03-29", "url": "https://questionsmedicales.fr/article/37034700", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1101/2023.03.24.23287710" } }, { "@type": "ScholarlyArticle", "name": "Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT).", "datePublished": "2022-07-01", "url": "https://questionsmedicales.fr/article/35834254", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1001/jamanetworkopen.2022.20680" } }, { "@type": "ScholarlyArticle", "name": "Dependent censoring bias assessment using inverse probability of censoring weights: Type 2 diabetes mellitus risk in patients initiating bisoprolol versus other antihypertensives in a Clinical Practice Research Datalink cohort study.", "datePublished": "2024-11-17", "url": "https://questionsmedicales.fr/article/39417364", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.57264/cer-2023-0027" } }, { "@type": "ScholarlyArticle", "name": "Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance.", "datePublished": "2023-03-04", "url": "https://questionsmedicales.fr/article/36880088", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1093/jacamr/dlad011" } }, { "@type": "ScholarlyArticle", "name": "Serum multi-cytokines screening identifies TRAIL and IL-10 as probable new biomarkers for prostate health index diagnostic utility adjustment in grey zone aggressive prostate cancer detection: A single-center data in China.", "datePublished": "2022-08-18", "url": "https://questionsmedicales.fr/article/36059480", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2022.901176" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Cellules", "item": "https://questionsmedicales.fr/mesh/D002477" }, { "@type": "ListItem", "position": 3, "name": "Thymocytes", "item": "https://questionsmedicales.fr/mesh/D060168" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Thymocytes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Thymocytes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Thymocytes", "description": "Comment diagnostiquer une anomalie des thymocytes ?\nQuels examens sont utilisés pour évaluer les thymocytes ?\nLes tests génétiques sont-ils utiles pour les thymocytes ?\nPeut-on évaluer la fonction des thymocytes ?\nQuels marqueurs sont utilisés pour identifier les thymocytes ?", "url": "https://questionsmedicales.fr/mesh/D060168?mesh_terms=Probability&page=273#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Thymocytes", "description": "Quels symptômes indiquent un problème avec les thymocytes ?\nLes anomalies des thymocytes causent-elles des symptômes spécifiques ?\nComment les thymocytes affectent-ils la santé globale ?\nLes symptômes d'une maladie des thymocytes sont-ils visibles ?\nLes symptômes varient-ils selon l'âge ?", "url": "https://questionsmedicales.fr/mesh/D060168?mesh_terms=Probability&page=273#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Thymocytes", "description": "Comment prévenir les maladies liées aux thymocytes ?\nY a-t-il des mesures préventives spécifiques ?\nLes dépistages réguliers sont-ils recommandés ?\nL'alimentation influence-t-elle la santé des thymocytes ?\nLe stress a-t-il un impact sur les thymocytes ?", "url": "https://questionsmedicales.fr/mesh/D060168?mesh_terms=Probability&page=273#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Thymocytes", "description": "Quels traitements existent pour les anomalies des thymocytes ?\nLa transplantation de thymus est-elle une option ?\nLes traitements ciblent-ils spécifiquement les thymocytes ?\nLes thérapies biologiques sont-elles efficaces ?\nLes traitements sont-ils personnalisés selon le patient ?", "url": "https://questionsmedicales.fr/mesh/D060168?mesh_terms=Probability&page=273#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Thymocytes", "description": "Quelles complications peuvent survenir avec des thymocytes anormaux ?\nLes troubles auto-immuns sont-ils liés aux thymocytes ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications sont-elles fréquentes ?", "url": "https://questionsmedicales.fr/mesh/D060168?mesh_terms=Probability&page=273#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Thymocytes", "description": "Quels sont les facteurs de risque pour les anomalies des thymocytes ?\nL'âge influence-t-il le risque d'anomalies thymiques ?\nLes maladies génétiques augmentent-elles le risque ?\nLe mode de vie joue-t-il un rôle dans le risque ?\nLes expositions environnementales sont-elles un facteur ?", "url": "https://questionsmedicales.fr/mesh/D060168?mesh_terms=Probability&page=273#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie des thymocytes ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des biopsies du thymus peuvent révéler des anomalies." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer les thymocytes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie par résonance magnétique et les analyses cytologiques sont courantes." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils utiles pour les thymocytes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent identifier des anomalies génétiques affectant le développement des thymocytes." } }, { "@type": "Question", "name": "Peut-on évaluer la fonction des thymocytes ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des tests fonctionnels mesurant la réponse immunitaire peuvent être effectués." } }, { "@type": "Question", "name": "Quels marqueurs sont utilisés pour identifier les thymocytes ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs CD4 et CD8 sont souvent utilisés pour caractériser les thymocytes." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème avec les thymocytes ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des infections fréquentes et une immunodéficience peuvent signaler des problèmes." } }, { "@type": "Question", "name": "Les anomalies des thymocytes causent-elles des symptômes spécifiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent entraîner des troubles auto-immuns et des lymphomes." } }, { "@type": "Question", "name": "Comment les thymocytes affectent-ils la santé globale ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des thymocytes dysfonctionnels peuvent compromettre la réponse immunitaire." } }, { "@type": "Question", "name": "Les symptômes d'une maladie des thymocytes sont-ils visibles ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent être subtils, souvent révélés par des infections récurrentes." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes enfants peuvent présenter des symptômes plus marqués." } }, { "@type": "Question", "name": "Comment prévenir les maladies liées aux thymocytes ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain et des vaccinations peuvent aider à prévenir les infections." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives spécifiques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les expositions aux agents pathogènes et maintenir une bonne hygiène." } }, { "@type": "Question", "name": "Les dépistages réguliers sont-ils recommandés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, surtout pour les personnes à risque d'immunodéficience." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle la santé des thymocytes ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut soutenir la fonction immunitaire et des thymocytes." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur les thymocytes ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut affecter la fonction des thymocytes et l'immunité." } }, { "@type": "Question", "name": "Quels traitements existent pour les anomalies des thymocytes ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des immunosuppresseurs et des thérapies géniques." } }, { "@type": "Question", "name": "La transplantation de thymus est-elle une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être envisagée pour les patients avec des déficits immunitaires sévères." } }, { "@type": "Question", "name": "Les traitements ciblent-ils spécifiquement les thymocytes ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certains traitements visent à restaurer la fonction des thymocytes." } }, { "@type": "Question", "name": "Les thérapies biologiques sont-elles efficaces ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent moduler la réponse immunitaire et améliorer la fonction des thymocytes." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés selon le patient ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des thymocytes anormaux ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des infections graves et des cancers comme les lymphomes peuvent se développer." } }, { "@type": "Question", "name": "Les troubles auto-immuns sont-ils liés aux thymocytes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des thymocytes dysfonctionnels peuvent contribuer à des maladies auto-immunes." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être traitées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Comment les complications affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent réduire la qualité de vie en augmentant la susceptibilité aux infections." } }, { "@type": "Question", "name": "Les complications sont-elles fréquentes ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent être fréquentes chez les personnes avec des anomalies thymiques." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les anomalies des thymocytes ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux et certaines infections virales augmentent le risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'anomalies thymiques ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes enfants et les personnes âgées sont plus à risque." } }, { "@type": "Question", "name": "Les maladies génétiques augmentent-elles le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines maladies génétiques peuvent prédisposer à des anomalies des thymocytes." } }, { "@type": "Question", "name": "Le mode de vie joue-t-il un rôle dans le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie malsain peut augmenter le risque d'anomalies immunitaires." } }, { "@type": "Question", "name": "Les expositions environnementales sont-elles un facteur ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines expositions environnementales peuvent affecter la santé des thymocytes." } } ] } ] }

Sources (2731 au total)

Cluster-Based Toxicity Estimation of Osteoradionecrosis via Unsupervised Machine Learning: Moving Beyond Single Dose-Parameter Normal Tissue Complication Probability by Using Whole Dose-Volume Histograms for Cohort Risk Stratification.

Given the limitations of extant models for normal tissue complication probability estimation for osteoradionecrosis (ORN) of the mandible, the purpose of this study was to enrich statistical inference... The analysis was conducted on retrospective data of 1,259 head and neck cancer (HNC) patients treated at the University of Texas MD Anderson Cancer Center between 2005 and 2015. The (structural) clust... The K-means clustering method identified six clusters among the DVHs. Based on the first five clusters, the dose-volume space was partitioned almost perfectly by the soft-margin SVM into distinct regi... This study presents an unsupervised-learning analysis of a large-scale data set to evaluate the risk of mandibular ORN among HNC patients. The results provide a visual risk-assessment tool (based on t...

Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT).

The cardiovascular and renal outcomes of angiotensin-II receptor blocker (ARB) and angiotensin-converting enzyme inhibitor (ACEI) treatment are well-known; however, few studies have evaluated initiati... To emulate a target trial to evaluate the cognitive outcomes of initiating an ARB- vs ACEI-based antihypertensive regimen in individuals at risk for mild cognitive impairment (MCI) and probable dement... Active comparator, new-user observational cohort study design using data from the Systolic Blood Pressure Intervention Trial (SPRINT), conducted November 2010 through July 2018. Marginal cause-specifi... New users of ARB vs ACEI during the first 12 months of trial follow-up.... Composite of adjudicated amnestic MCI or PD.... Of 9361 participants, 727 and 1313 new users of an ARB or ACEI, respectively, with well-balanced baseline characteristics between medication exposure groups after inverse probability weighting (mean [... In this observational cohort study of US adults at high cardiovascular disease risk, there was no difference in the rate of amnestic MCI or PD among new users of an ARB compared with ACEI, although 95...

Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance.

To assess the relationship between renal function and efficacy/safety of imipenem/cilastatin/relebactam for the treatment of hospital-acquired/ventilator-associated pneumonia (HABP/VABP) from RESTORE-... Adults with HABP/VABP were randomized 1:1 to IV imipenem/cilastatin/relebactam 1.25 g or piperacillin/tazobactam 4.5 g every 6 h for 7-14 days. Initial doses were selected by CL... The modified ITT population comprised those with normal renal function (... Prescribing information-defined dose adjustments in participants with baseline RI and full dosing of imipenem/cilastatin/relebactam 1.25 g every 6 h for participants with normal renal function or augm...

Serum multi-cytokines screening identifies TRAIL and IL-10 as probable new biomarkers for prostate health index diagnostic utility adjustment in grey zone aggressive prostate cancer detection: A single-center data in China.

To identify less invasive and easily applicable serum cytokine-derived biomarkers which contribute to the diagnostic utility and risk assessment ability of the prostate health index (PHI) based multiv... Serum 45 cytokines screening was performed in a small training cohort consisting of 10 sera by Luminex liquid array-based multiplexed immunoassays and identified TRAIL and IL-10 as new biomarkers for ... TRAIL and IL-10 were identified as potential serum biomarkers for AG PCa detection by the result of multi-cytokines screening in the univariate analysis, while multivariable logistic regression confir... We suggest a significant advantage for the PHI-based multivariate combinations of serum TRAIL and IL-10 comparing to PHI or other serum-derived biomarkers alone in the detection and risk stratificatio...

Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.

Switching from intravenous antibiotic therapy to oral antibiotic therapy among neonates is not yet practised in high-income settings due to uncertainties about exposure and safety. We aimed to assess ... In this multicentre, randomised, open-label, non-inferiority trial, patients were recruited at 17 hospitals in the Netherlands. Neonates (postmenstrual age ≥35 weeks, postnatal age 0-28 days, bodyweig... Between Feb 8, 2018 and May 12, 2021, 510 neonates were randomly assigned (n=255 oral amoxicillin-clavulanic group; n=255 intravenous antibiotic group). After excluding those who withdrew consent (n=4... An early intravenous-to-oral antibiotic switch with amoxicillin-clavulanic acid is non-inferior to a full course of intravenous antibiotics in neonates with probable bacterial infection and is not ass... The Netherlands Organization for Health Research and Development, Innovatiefonds Zorgverzekeraars, and the Sophia Foundation for Scientific Research....

'I probably wouldn't want to talk about anything too personal': A qualitative exploration of how issues of privacy, confidentiality and surveillance in the home impact on access and engagement with online services and spaces for care-experienced young people.

This paper draws on a qualitative interview-based study that explored online mental health and wellbeing interventions and services for care-experienced young people. The study involved young people (...

Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047).

The risk and survival of patients with non-small cell lung cancer (NSCLC) with pre-existing autoimmune disorders (AIDs) receiving immune checkpoint blockade (ICB) therapy have not been clearly establi... This multi-institutional, retrospective cohort study was conducted in collaboration with 20 centers in Japan.... In total, 229 patients with advanced or recurrent NSCLC and pre-existing AID, with or without ICB treatment from January 2010-February 2020, were included and analyzed. Among 69 patients who received ... These findings revealed a novel risk factor for AID flares following ICB treatment, that is the diagnosis of NSCLC within 1 year of AID diagnosis, and showed that ICBs may improve survival in this pop...

Mandibular dose-volume predicts time-to-osteoradionecrosis in an actuarial normal-tissue complication probability (NTCP) model: External validation of right-censored clinico-dosimetric and competing risk application across international multi-institutional observational cohorts and online graphical user interface clinical support tool assessment.

Existing studies on osteoradionecrosis of the jaw (ORNJ) have primarily used cross-sectional data, assessing risk factors at a single time point. Determining the time-to-event profile of ORNJ has impo... Demographic, clinical and dosimetric data were retrospectively obtained for a clinical observational cohort of 1129 patients with HNC treated with radiotherapy (RT) at The University of Texas MD Ander... Our model identified that each unit increase in D25% is significantly associated with a 12% shorter time to ORNJ (Adjusted Time Ratio [ATR] 0·88, p<0·005); pre-RT dental extractions was associated to ... This study is the first to demonstrate a direct relationship between radiation dose and the time to ORNJ onset, providing a novel characterization of the impact of delivered dose not only on the proba... This work was supported by various funding sources including NIH, NIDCR, NCI, NAPT, NASA, BCM, Affirmed Pharma, CRUK, KWF Dutch Cancer Society, NWO ZonMw, and the Apache Corporation....